. Author manuscript; available in PMC: 2021 Oct 1.

Published in final edited form as: Small Struct. 2020 Sep 9;1(1):2000018. doi: 10.1002/sstr.202000018

Table 2.

Summary of PNPs for targeted cancer therapy and CTC capture

Therapeutic modality	Core	Drug/Active agent	Cancer model	Ref.
Chemotherapy	PLGA	docetaxel	A549 mouse xenograft	[62]
	gelatin nanogels (GN)	irinotecan	HT-29 mouse xenograft	[63]
	chitosan oligosaccharide -PLGA copolymer.	bufalin	H22 mouse xenograft	[64]
	black phosphorus quantum dots	Hederagenin	n/a	[65]
	nanostructured lipid carrier	paclitaxel	n/a	[66]
RNA inference	zeolitic imidazolate framework-8 (ZIF-8) metal-organic frameworks (MOFs)	siRNA	SK-BR-3 mouse xenograft	[67]
PTT/PDT	PLGA	verteporfin (a photodynamic agent)	4T1 mouse xenograft	[69]
PTT/PDT	W18O49 nanoparticles	W18O49	Raji lymphoma mouse xenograft	[70]
Combinatorial therapy	acrylamide-based nanogels	TRAIL and doxorubicin	Mouse models of MDA-MB-231 xenograft and metastasis	[71]
	hollow MnO2 NPs	bufalin	H22 mouse xenograft	[73]
	mesoporous silica-coated bismuth nanorod (as both a radio sensitizer and a photothermal sensitizer)	n/a	4T1 mouse xenograft	[74]
CTC capture and killing	synthetic silica particles	TRAIL	Experimental lung metastasis by i.v. injection of MDA-MB-231 cells	[75]
CTC capture and killing	Iron oxide magnetic nanoparticles	Dye-conjugated antibody on the surface for detection	MCF-7 cells spiked in whole blood obtained from healthy donors and breast cancer patient blood samples	[76]